Haemonetics (NYSE: HAE) reported Q2 EPS of $0.99, $0.10 better than the analyst estimate of $0.89. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $313.12 million.

For earnings history and earnings-related data on Haemonetics (HAE) click here.